Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Results from the APHINITY trial of two HER2 targeted agents with chemo

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 3592
Rating:

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Prof von Minckwitz speaks with ecancer at ASCO 2017 about results from the APHINITY trial, a phase III clinical trial of 4,805 women with HER2-positive breast cancer.

By adding a second HER2 targeted medicine, pertuzumab, to standard of care trastuzumab after surgery, he describes how the risk of patients developing invasive disease is reduced.

Prof von Minckwitz considers the associated toxicity of this double-hit, notably cardiac toxicities, and discusses the possible substitution of trastuzumab for a biosimilar.

For more on these results, watch his presentation of findings at a press briefing.

 

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation